| Literature DB >> 31581570 |
Federica Laudisi1, Carmine Stolfi2, Giovanni Monteleone3.
Abstract
In physiological conditions, the gut is heavily infiltrated with various subsets of inflammatory cells, whose activity is tightly controlled by counter-regulatory mechanisms. Defects in such mechanisms can favour the development of chronic intestinal disorders, such as Crohn's disease (CD) and ulcerative colitis (UC), the principal forms of inflammatory bowel diseases (IBD) in humans, as well as systemic disorders. Over the last years, the frequency of intestinal and systemic immune-inflammatory disorders has increased in previously low incidence areas, likely due to the Westernization of lifestyles, including dietary habits. The Western diet is characterized by high consumption of proteins, saturated fats and sweets, as well as by a broad use of food additives (e.g., emulsifiers, bulking agents), which are used to preserve and enhance food quality. Accumulating evidence suggests that food additives can perturb gut homeostasis, thereby contributing to promote tissue-damaging inflammatory responses. For instance, mice given the emulsifiers carboxymethylcellulose and polysorbate 80 develop dysbiosis with overgrowth of mucus-degrading bacteria. Such an effect triggers colitis in animals deficient in either interleukin-10, a cytokine exerting anti-inflammatory and regulatory functions, or Toll-like receptor 5, a receptor recognizing the bacterial flagellin. Similarly, the polysaccharide maltodextrin induces endoplasmic reticulum stress in intestinal goblet cells, thereby impairing mucus release and increasing host susceptibility to colitis. In this review, we report and discuss the current knowledge about the impact of food additives on gut homeostasis and their potential contribution to the development of inflammatory disorders.Entities:
Keywords: IBD; Western diet; colitis; dysbiosis; emulsifiers; maltodextrin; microbiota
Mesh:
Substances:
Year: 2019 PMID: 31581570 PMCID: PMC6835893 DOI: 10.3390/nu11102334
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Effects of food additives on gut homeostasis. All the indicated substances were used in pre-clinical studies and administered orally. All the food additives were dissolved in drinking water unless otherwise indicated in the “Experimental dosage”.
| Food Additive | Category | Effect on Gut Homeostasis | Experimental | Reference |
|---|---|---|---|---|
| CMC/P80 | Emulsifier | Dysbiosis and metabolic syndrome; colitis in | 1% | [ |
| Colorectal cancer | 1% | [ | ||
| Expansion of human pro-inflammatory bacteria | 1, 0.5, 0.25 or 0.10% | [ | ||
| Sex-specific behavioural and neural alterations in mice | 1% | [ | ||
| MDX | Coating and thickening agent | Necrotizing enterocolitis in preterm piglets | 47 or 55.2 g/L | [ |
| Outgrowth of AIEC strain | 0.4% in medium | [ | ||
| Impaired response to | 5% | [ | ||
| Decreased mucus production, increased susceptibility to colitis, low-grade intestinal inflammation | 5% | [ | ||
| NAS | Non-caloric artificial sweetener | Intestinal dysbiosis and glucose intolerance | Saccharine: 5%; Sucralose 5%; Aspartame 4% | [ |
| Alteration of host microbiota and related metabolites; liver inflammation. | 0.1 mg/mL | [ | ||
| Alteration of microbiota composition and related metabolites of mouse pups; impairment of their hepatic detoxification mechanisms. | 0.2 mg/20 µL | [ | ||
| Neotame | Non-caloric artificial sweetener | Intestinal dysbiosis; increased secretion of cholesterol and lipid in faeces. | 0.75 mg/Kg by oral gavage | [ |
| Splenda | Non-caloric artificial sweetener | Intestinal dysbiosis and intestinal inflammation; | 1.08–3.5 mg/mL | [ |
| TiO2 | Food colorant | Increased cytokine production and impaired phagocyte activity (at the higher dose). | 0.05–50 µg/mL | [ |
| Intestinal inflammation and dysbiosis, ROS release, NLRP3 inflammasome activation and IL-1β and IL-18 cytokine release; increased intestinal permeability | 10-50-500 mg/Kg by oral gavage | [ | ||
| Accumulation in Peyer’s Patches; higher frequency of resident DCs and decreased number of regulatory T cells | 10 mg/Kg | [ | ||
| Impairment of the probiotic taxa ( | 0.1% in food | [ | ||
| Alteration of bacterial metabolites; decrease in mucus-related gene expression (i.e., | 2-10-50 mg/Kg | [ | ||
| Increased fasting blood glucose levels and expression of diabetes mellitus-related genes in pregnant rats | 5 mg/Kg | [ | ||
| SAS | Thickening agent/foam controller | NLRP3 inflammasome activation in DCs and IL-1β cytokine release upon apoptosis and ROS production. | 20 or 40 µg/cm2 in medium | [ |
| AgNPs | Antimicrobial agent | Intestinal microvilli and gland damage, body weight loss, intestinal dysbiosis | 46-460-4600 ppb in food | [ |
| Development of anxiety-like behaviours | 3.6 mg/Kg | [ | ||
| ε-Polylysine | Antimicrobial agent | Intestinal dysbiosis. | 1.4 × 10−6 g/ g body weight | [ |
| TCS | Antimicrobial agent | Intestinal dysbiosis, low-grade intestinal inflammation and colitis-associated colon carcinogenesis. | 5-10-80 ppm | [ |
Abbreviations: ADI: acceptable daily intake; AgNPs: silver nanoparticles; AIEC: adherent invasive E. coli; CMC: carboxymethylcellulose; DCs: dendritic cells; Defb3: defensin beta 3; DSS: dextran sodium sulfate; GRAS: generally recognized as safe; IL: interleukin; MDX: maltodextrin; Muc-2: mucin-2; NAS: non-caloric artificial sweetener; NLRP3: NACHT, LRR and PYD domains-containing protein 3; P80: polysorbate 80; ROS: reactive oxygen species; SAS: synthetic amorphous silica; TCS: triclosan; TiO2: titanium dioxide; TLR: toll-like receptor.